Paradigm was previously granted patents by US Patent and Trademark Office for the treatment of BME lesions (2015) which occurs in practically all serious cases of OA. For pharmaceuticals, patents granted are for 25 years so long as you keep paying the fees.
I think this is just one of the many avenues they are exploring to extend their portfolio of patents for protection. Some will be successful, some won't.
You commonly see this in the industry - companies that already have valuable patents, will rightly continue to see if they can reformulate, redesign, reengineer some aspect of their IP to make it 'new' again, to get another patent that either demonstrates improved efficacy, or effectiveness in a new application to broaden their markets. The aim ultimately is either to enable it to enter new or grow their markets, or just to extend the protected life of what IP they have.
Some of it will be considered to be like Malibu Stacey's new hat - interesting, but not unique and innovative enough.
While disappointing, PAR still has more than a leg to stand on.
PAR Price at posting:
$1.11 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)